$280 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 31 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 61.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | Sell | IMMUNOMEDICS INC | $42,816,000 | -61.9% | 2,055,500 | -56.7% | 15.27% | -23.7% |
| ASMB | Sell | ASSEMBLY BIOSCIENCES INC | $34,540,000 | -24.2% | 930,000 | -20.0% | 12.32% | +51.9% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $25,005,000 | -51.5% | 2,222,701 | -44.8% | 8.92% | -2.7% |
| KDMN | Sell | KADMON HLDGS INC | $24,699,000 | -31.7% | 7,395,000 | -18.4% | 8.81% | +36.9% |
| CEMI | CHEMBIO DIAGNOSTICS INC | $21,321,000 | -5.4% | 2,030,533 | 0.0% | 7.60% | +89.6% | |
| ARWR | Sell | ARROWHEAD PHARMACEUTICALS IN | $14,857,000 | +6.0% | 775,000 | -24.8% | 5.30% | +112.5% |
| IRIX | Sell | IRIDEX CORP | $12,367,000 | -11.2% | 1,947,500 | -2.6% | 4.41% | +78.0% |
| CASM | CAS MED SYS INC | $12,001,000 | +16.9% | 5,263,508 | 0.0% | 4.28% | +134.3% | |
| VCYT | Sell | VERACYTE INC | $10,433,000 | -58.0% | 1,092,500 | -58.9% | 3.72% | -15.9% |
| XBI | SPDR SERIES TRUSTput | $9,587,000 | +0.7% | 100,000 | 0.0% | 3.42% | +101.8% | |
| REGN | REGENERON PHARMACEUTICALSput | $8,081,000 | +17.1% | 20,000 | 0.0% | 2.88% | +134.7% | |
| ARGX | Sell | ARGENX SEsponsored adr | $7,963,000 | -78.8% | 105,000 | -76.8% | 2.84% | -57.5% |
| MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $7,066,000 | -27.4% | 33,000 | -5.2% | 2.52% | +45.4% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $6,369,000 | +53.8% | 482,500 | +7.2% | 2.27% | +208.3% |
| CHRS | Buy | COHERUS BIOSCIENCES INC | $5,833,000 | +20.8% | 353,500 | +2.5% | 2.08% | +142.0% |
| ASMB | ASSEMBLY BIOSCIENCES INCcall | $5,478,000 | -5.3% | 147,500 | 0.0% | 1.95% | +89.9% | |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $5,066,000 | -75.5% | 71,500 | -77.0% | 1.81% | -51.0% |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO L | $4,975,000 | -21.3% | 132,500 | -17.2% | 1.78% | +57.6% |
| ARWR | ARROWHEAD PHARMACEUTICALS INcall | $3,834,000 | +41.0% | 200,000 | 0.0% | 1.37% | +182.6% | |
| ACER | ACER THERAPEUTICS INC | $3,370,000 | +42.8% | 109,270 | 0.0% | 1.20% | +186.2% | |
| VRAY | Sell | VIEWRAY INC | $2,916,000 | -71.8% | 311,500 | -79.2% | 1.04% | -43.5% |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $2,849,000 | – | 128,844 | +100.0% | 1.02% | – |
| MGTA | MAGENTA THERAPEUTICS INC | $2,042,000 | -11.0% | 170,000 | 0.0% | 0.73% | +78.0% | |
| BHVN | BIOHAVEN PHARMACTL HLDG CO Lcall | $2,020,000 | -5.0% | 53,800 | 0.0% | 0.72% | +90.7% | |
| ECYT | New | ENDOCYTE INC | $1,634,000 | – | 92,000 | +100.0% | 0.58% | – |
| AMRN | New | AMARIN CORP PLCspons adr new | $1,155,000 | – | 71,000 | +100.0% | 0.41% | – |
| CHRS | COHERUS BIOSCIENCES INCcall | $825,000 | +17.9% | 50,000 | 0.0% | 0.29% | +135.2% | |
| AMAG | Sell | AMAG PHARMACEUTICALS INCput | $800,000 | -17.9% | 40,000 | -20.0% | 0.28% | +63.8% |
| ALIM | Sell | ALIMERA SCIENCES INC | $262,000 | -72.5% | 267,500 | -72.5% | 0.09% | -45.3% |
| GTXI | New | GTX INC DELput | $157,000 | – | 100,000 | +100.0% | 0.06% | – |
| ONS | ONCOBIOLOGICS INC | $29,000 | +16.0% | 29,082 | 0.0% | 0.01% | +150.0% | |
| TRXC | Exit | TRANSENTERIX INCput | $0 | – | -25,000 | -100.0% | -0.02% | – |
| RMTI | Exit | ROCKWELL MED INCput | $0 | – | -25,000 | -100.0% | -0.02% | – |
| MNKD | Exit | MANNKIND CORPput | $0 | – | -107,500 | -100.0% | -0.04% | – |
| ZYNE | Exit | ZYNERBA PHARMACEUTICALS INCput | $0 | – | -50,000 | -100.0% | -0.09% | – |
| PTE | Exit | POLARITYTE INCput | $0 | – | -25,000 | -100.0% | -0.10% | – |
| VIVE | Exit | VIVEVE MED INC | $0 | – | -267,500 | -100.0% | -0.13% | – |
| STAA | Exit | STAAR SURGICAL COput | $0 | – | -25,000 | -100.0% | -0.14% | – |
| OSUR | Exit | ORASURE TECHNOLOGIES INCput | $0 | – | -50,000 | -100.0% | -0.15% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC NEput | $0 | – | -25,000 | -100.0% | -0.17% | – |
| FTSV | Exit | FORTY SEVEN INC | $0 | – | -73,000 | -100.0% | -0.21% | – |
| DB | Exit | DEUTSCHE BANK AGput | $0 | – | -150,000 | -100.0% | -0.28% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -100,000 | -100.0% | -0.31% | – |
| EDIT | Exit | EDITAS MEDICINE INCcall | $0 | – | -50,000 | -100.0% | -0.32% | – |
| VCEL | Exit | VERICEL CORP | $0 | – | -190,055 | -100.0% | -0.33% | – |
| ZGNX | Exit | ZOGENIX INCput | $0 | – | -45,000 | -100.0% | -0.35% | – |
| TSRO | Exit | TESARO INC | $0 | – | -50,000 | -100.0% | -0.40% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INCcall | $0 | – | -190,000 | -100.0% | -0.43% | – |
| ZFGN | Exit | ZAFGEN INC | $0 | – | -250,000 | -100.0% | -0.46% | – |
| FENC | Exit | FENNEC PHARMACEUTICALS INC | $0 | – | -250,000 | -100.0% | -0.46% | – |
| Exit | INOTEK PHARMACEUTICALS CORPnote 5.750% 8/0 | $0 | – | -3,000,000 | -100.0% | -0.54% | – | |
| MEIP | Exit | MEI PHARMA INC | $0 | – | -880,087 | -100.0% | -0.62% | – |
| ZGNX | Exit | ZOGENIX INCcall | $0 | – | -82,500 | -100.0% | -0.65% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -168,000 | -100.0% | -0.66% | – |
| AERI | Exit | AERIE PHARMACEUTICALS INCput | $0 | – | -61,000 | -100.0% | -0.73% | – |
| CUTR | Exit | CUTERA INC | $0 | – | -105,000 | -100.0% | -0.75% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -110,500 | -100.0% | -0.87% | – |
| OBSV | Exit | OBSEVA SA | $0 | – | -424,300 | -100.0% | -1.14% | – |
| EEM | Exit | ISHARES TRput | $0 | – | -150,000 | -100.0% | -1.16% | – |
| VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -750,000 | -100.0% | -1.27% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -60,000 | -100.0% | -1.41% | – |
| CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -830,000 | -100.0% | -1.72% | – |
| Exit | INTEC PHARMA LTD JERUSALEM | $0 | – | -2,962,568 | -100.0% | -2.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-07
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.